Invivyd (IVVD) Projected to Post Quarterly Earnings on Thursday

Invivyd (NASDAQ:IVVD) is expected to announce its Q1 2026 results before the market opens on Thursday, May 7th. Analysts expect the company to announce earnings of ($0.08) per share and revenue of $18.0420 million for the quarter. Parties can check the company’s upcoming Q1 2026 earning summary page for the latest details on the call scheduled for Thursday, May 14, 2026 at 8:30 AM ET.

Invivyd Price Performance

NASDAQ:IVVD traded down $0.08 on Tuesday, hitting $1.39. 2,391,198 shares of the company’s stock were exchanged, compared to its average volume of 2,901,233. The firm has a 50-day moving average price of $1.57 and a 200-day moving average price of $1.93. Invivyd has a 52 week low of $0.48 and a 52 week high of $3.07. The company has a market cap of $393.09 million, a P/E ratio of -4.34 and a beta of 0.71.

Analysts Set New Price Targets

IVVD has been the topic of several analyst reports. BTIG Research reissued a “buy” rating and set a $10.00 price target on shares of Invivyd in a research report on Thursday, February 26th. Weiss Ratings reissued a “sell (d-)” rating on shares of Invivyd in a research report on Wednesday, April 29th. Three investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $8.00.

Insider Buying and Selling

In related news, insider Julie Green sold 20,964 shares of Invivyd stock in a transaction dated Wednesday, February 18th. The stock was sold at an average price of $1.58, for a total transaction of $33,123.12. Following the completion of the transaction, the insider owned 107,717 shares in the company, valued at approximately $170,192.86. This trade represents a 16.29% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Jill Andersen sold 34,939 shares of Invivyd stock in a transaction dated Wednesday, February 18th. The stock was sold at an average price of $1.58, for a total value of $55,203.62. Following the transaction, the insider owned 181,736 shares of the company’s stock, valued at $287,142.88. The trade was a 16.13% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 227,172 shares of company stock worth $354,534 in the last 90 days. 12.25% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Invivyd

Hedge funds and other institutional investors have recently bought and sold shares of the business. Marshall Wace LLP bought a new position in Invivyd during the second quarter worth about $158,000. Jain Global LLC bought a new position in Invivyd during the fourth quarter worth about $122,000. Squarepoint Ops LLC grew its holdings in Invivyd by 188.9% during the third quarter. Squarepoint Ops LLC now owns 107,831 shares of the company’s stock worth $119,000 after purchasing an additional 70,508 shares during the period. Bridgeway Capital Management LLC bought a new position in Invivyd during the third quarter worth about $109,000. Finally, Mangrove Partners IM LLC bought a new position in Invivyd during the fourth quarter worth about $104,000. Institutional investors own 70.36% of the company’s stock.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19.